Me has faced an uncertain future after struggles to find a profitable business model and privacy concerns related to ...

Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.

The once-popular genetic testing company will be acquired by Regeneron after filing for bankruptcy, but the questions about ...

Regeneron Pharmaceuticals is acquiring the assets of 23andMe for $256 million, excluding its Lemonaid Health business, as the ...

On Monday, Regeneron Pharmaceuticals announced that it would acquire most of 23andMe's assets for $256 million. According to ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug discovery.

Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, ...

The proposed sale is expected to close in the third quarter, subject to approval by the U.S. Bankruptcy Court for the Eastern ...

Genetics and biotechnology company 23andMe today announced it will be acquired by Regeneron Pharmaceuticals for a purchase price of $256 million.

Drugmaker acquires DNA testing firm and gains access to massive genetic database ● Consumer genome services to continue; ...